A systematic review and meta-analysis evaluating whether using Daiichi Sankyo’s Radicava (edaravone) and Sanofi’s Rilutek (riluzole) in combination provides additional clinical benefit compared with Rilutek alone in patients with amyotrophic lateral sclerosis (ALS) has found no added benefit.
The data was revealed in a poster presentation on 27 June at the 12th Congress of the European Academy of Neurology (EAN) 2026.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
The analysis included five studies comprising 548 patients, of whom 39.4% received combination therapy. Functional outcomes were evaluated using the ALS Functional Rating Scale-Revised (ALSFRS-R) progression. The individual studies showed inconsistent treatment effects. While some studies numerically favoured combination therapy, others favoured Rilutek monotherapy or demonstrated negligible differences. It was therefore unsurprising that the pooled analysis demonstrated no significant differences between treatment groups with Radicava added to Rilutek compared with Rilutek alone.
The pooled standardised mean difference (SMD) was 0.20, indicating that any observed numerical differences were small and not statistically meaningful. Importantly, the analysis reported moderate heterogeneity (I²=63%), suggesting variability among the included studies that may reflect differences in patient populations, disease stage, treatment duration, study design, or outcome assessment.
Similarly to functional progression outcomes, the addition of edaravone did not significantly improve survival outcomes compared with riluzole monotherapy. The pooled odds ratio for mortality was 1.37 with moderate heterogeneity (I²=60%). The wide confidence interval reflects considerable statistical uncertainty and is likely limited due to the relatively small number of mortality studies included.
From a competitive landscape perspective, this data is unlikely to substantially alter current treatment algorithms, where riluzole monotherapy continues to serve as the backbone of pharmacological management. These results are also generally consistent with the broader published literature, where edaravone monotherapy has demonstrated the greatest benefit primarily in carefully selected patients with early-stage ALS and preserved functional status, rather than across the overall ALS population. The findings reinforce the position of riluzole monotherapy as the standard of care in ALS management, given that the benefit of adding edaravone continues to be uncertain.
While these findings do not negate the potential benefit observed in selected patients, they highlight the continued uncertainty regarding the routine use of combination therapy across the broader ALS population and underscore the need for more robust, adequately powered randomised studies to fully understand the role of riluzole/edaravone combination therapy for ALS. However, the absence of a clear additive benefit from edaravone may reinforce the increasing clinical focus on precision therapies targeting genetically defined patient populations.
